muc3 antibody  (NSJ Bioreagents)

Journal: Immunity, Inflammation and Disease

Article Title: Alleviating effect of Nexrutine on mucosal inflammation in mice with ulcerative colitis: Involvement of the RELA suppression

doi: 10.1002/iid3.1147

Figure Lengend Snippet: Nexrutine alleviates inflammation and colonic mucosal barrier damage in mice with UC. A mouse model of UC was induced by administration of 3% DSS in drinking water. The model mice were treated with Nexrutine (300 mg/kg or 600 mg/kg) or the positive control regimen Mesalazine (195 mg/kg). (A) Body weight change of mice in each group; (B) DAI score of mice in each group; (C) length of whole colon of mice in each group; (D) pathological injury score in mouse colon tissues evaluated by HE staining; (E) concentrations of IL‐1β, IL‐6, TNF‐α, and IL‐10 in mouse colon tissues analyzed by ELISA kits; (F) expression of MUC3, Claudin‐1, and ZO‐1 in mouse colon tissues determined by IHC assay. In each group, n = 8. Differences were analyzed by the one‐way (B, C, D) or two‐way (A, E, F) ANOVA. * p < .05 versus the control group; # p < .05 versus the DSS group. DAI, disease activity index; DSS, dextran sulfate sodium; HE, hematoxylin and eosin; IHC, immunohistochemistry; UC, ulcerative colitis.

Article Snippet: Subsequently, the sections were incubated with antibodies of mucin 3 (MUC3; 1:500, PAB031Mu01; Cloud‐Clone Corp.), Claudin‐1 (1:500, ab211737; Abcam Inc.), and tight junction protein 1 (ZO‐1, 1:500, ab276131; Abcam) overnight at 4°C, followed by incubation with goat anti‐rabbit IgG (1: 1,000, ab6721; Abcam) at 37°C for 20 min.

Techniques: Positive Control, Staining, Enzyme-linked Immunosorbent Assay, Expressing, Activity Assay, Immunohistochemistry

Journal: Immunity, Inflammation and Disease

Article Title: Alleviating effect of Nexrutine on mucosal inflammation in mice with ulcerative colitis: Involvement of the RELA suppression

doi: 10.1002/iid3.1147

Figure Lengend Snippet: Restoration of RELA aggravates inflammatory injury in mouse colon tissues. Mice were injected with Ad‐RELA through the mesenteric artery, followed by the 3% DSS and Nexrutine (300 mg/kg) treatments. (A) Body weight change of mice in each group; (B) DAI score of mice in each group; (C) length of whole colon of mice in each group; (D) pathological injury score in mouse colon tissues evaluated by HE staining; (E) concentrations of IL‐1β, IL‐6, TNF‐α, and IL‐10 in mouse colon tissues analyzed by ELISA kits; (F) expression of MUC3, Claudin‐1, and ZO‐1 in mouse colon tissues determined by IHC assay. In each group, n = 8. Differences were analyzed by the unpaired t test (B–D) or two‐way ANOVA (A, E, F). * p < .05 versus the control group; # p < .05 versus the DSS group. DAI, disease activity index; DSS, dextran sulfate sodium; HE, hematoxylin and eosin; IHC, immunohistochemistry.

Article Snippet: Subsequently, the sections were incubated with antibodies of mucin 3 (MUC3; 1:500, PAB031Mu01; Cloud‐Clone Corp.), Claudin‐1 (1:500, ab211737; Abcam Inc.), and tight junction protein 1 (ZO‐1, 1:500, ab276131; Abcam) overnight at 4°C, followed by incubation with goat anti‐rabbit IgG (1: 1,000, ab6721; Abcam) at 37°C for 20 min.

Techniques: Injection, Staining, Enzyme-linked Immunosorbent Assay, Expressing, Activity Assay, Immunohistochemistry

Journal: Inflammatory bowel diseases

Article Title: Aberrant Mucin Expression Profiles Associate With Pediatric Inflammatory Bowel Disease Presentation and Activity.

doi: 10.1093/ibd/izac217

Figure Lengend Snippet: Figure 1. Expression of mucins in the colon of pediatric inflammatory bowel disease (IBD) patients and non-IBD control subjects. A, Relative messenger RNA (mRNA) expression of MUC1, MUC2, MUC3A, MUC3B, MUC4, and MUC13 in inflamed and noninflamed colonic tissue of IBD patients and non-IBD control subjects. Significant differences are indicated by *P < .05; **P < .01; ***P < .001 (1-way analysis of variance or Kruskal-Wallis, Tukey ,and Dunn multiple comparison post hoc test). B, Immunohistochemical analysis of MUC1, MUC2, MUC3, MUC4, and MUC13 expression in colonic biopsies from non-IBD control subjects and IBD patients. Representative images were selected. Scale bars = 20 μm.

Article Snippet: Five-micrometer cross-sections were deparaffinized, rehydrated, and used for immunohistochemical stainings using target specific primary antibodies and visualization with a secondary streptavidin–horseradish peroxidaseconjugated antibody and AEC (3-amino-9-ethylcarbazole) substrate to detect the expression and localization of MUC1 (AF6298; R&D systems; 1:500), MUC2 (NBP1-31,231; Novus Biologicals; 1:2000), MUC3 (NBP2-44,434; Novus Biologicals; 1:100), MUC4 (NBP1-52193; Novus Biologicals; 1:3000), and MUC13 (MABC209; Merck Millipore; 1:1000).

Techniques: Expressing, Control, Comparison, Immunohistochemical staining

Journal: Gut and Liver

Article Title: MUC Expression in Gallbladder Epithelial Tissues in Cholesterol-Associated Gallbladder Disease

doi: 10.5009/gnl15600

Figure Lengend Snippet: Immunohistochemistry (×200) of a healthy gallbladder. MUC3, MUC5AC, MUC5B, and MUC6 were expressed in the superficial epithelium and folds (arrows). MUC3 and MUC5B were the most prominently expressed proteins.

Article Snippet: After 10 minutes of blocking, 1:20 goat antihuman MUC3, MU-C5AC, MUC5B, and MUC6 polyclonal antibodies (Santa Cruz Inc., Santa Cruz, CA, USA) were added for 1 hour.

Techniques: Immunohistochemistry

Journal: Gut and Liver

Article Title: MUC Expression in Gallbladder Epithelial Tissues in Cholesterol-Associated Gallbladder Disease

doi: 10.5009/gnl15600

Figure Lengend Snippet: Immunohistochemistry (×200) in gallbladder tissues from patients with chole-cystitis or cholesterolosis combined with cholesterol stones. MUC3, MUC5AC, and MUC5B were expressed in the superficial epithelium and folds (arrows). The expression of MUC3 and MUC5B was more prominent in the cholesterol stone groups with cholecystitis or cholesterolosis than in normal controls.

Article Snippet: After 10 minutes of blocking, 1:20 goat antihuman MUC3, MU-C5AC, MUC5B, and MUC6 polyclonal antibodies (Santa Cruz Inc., Santa Cruz, CA, USA) were added for 1 hour.

Techniques: Immunohistochemistry, Expressing

Journal: Gut and Liver

Article Title: MUC Expression in Gallbladder Epithelial Tissues in Cholesterol-Associated Gallbladder Disease

doi: 10.5009/gnl15600

Figure Lengend Snippet: Immunohistochemistry (×200) in cholesterol polyp tissue. MUC3, MUC5AC, and MUC5B were expressed in the superficial epithelium and folds (arrows). MUC3 and MUC5B expression levels were slightly increased in the cholesterol polyp group compared to the normal controls.

Article Snippet: After 10 minutes of blocking, 1:20 goat antihuman MUC3, MU-C5AC, MUC5B, and MUC6 polyclonal antibodies (Santa Cruz Inc., Santa Cruz, CA, USA) were added for 1 hour.

Techniques: Immunohistochemistry, Expressing

Journal: Gut and Liver

Article Title: MUC Expression in Gallbladder Epithelial Tissues in Cholesterol-Associated Gallbladder Disease

doi: 10.5009/gnl15600

Figure Lengend Snippet: Mucin Expression in Gallbladder Tissue as Shown by Immunohistochemistry

Article Snippet: After 10 minutes of blocking, 1:20 goat antihuman MUC3, MU-C5AC, MUC5B, and MUC6 polyclonal antibodies (Santa Cruz Inc., Santa Cruz, CA, USA) were added for 1 hour.

Techniques: Expressing

Journal: Gut and Liver

Article Title: MUC Expression in Gallbladder Epithelial Tissues in Cholesterol-Associated Gallbladder Disease

doi: 10.5009/gnl15600

Figure Lengend Snippet: MUC protein expression in bile, gallbladder (GB) tissue and canine gallbladder epithelial cells (GBECs) as shown by dot/slot blotting. Bile and gallbladder tissues from patients with cholecystitis and cholesterol stones commonly showed increased expression of MUC3 and MUC5B. Slightly increased levels of MUC3, MUC5B, and MUC6 were observed following treatment of canine GBECs with lipopolysaccharide.

Article Snippet: After 10 minutes of blocking, 1:20 goat antihuman MUC3, MU-C5AC, MUC5B, and MUC6 polyclonal antibodies (Santa Cruz Inc., Santa Cruz, CA, USA) were added for 1 hour.

Techniques: Expressing

Journal: Gut and Liver

Article Title: MUC Expression in Gallbladder Epithelial Tissues in Cholesterol-Associated Gallbladder Disease

doi: 10.5009/gnl15600

Figure Lengend Snippet: MUC gene expression in gallbladder tissues. Both MUC3 and MUC5B mRNA were upregulated in the cholecystitis with cholesterol stone (S) and cholesterol polyp (P) groups compared with the control group (C) (p<0.05). Lane 1, normal control; Lanes 2 and 3, cholesterol polyp; Lanes 4 and 5, cholecystitis with cholesterol stone.

Article Snippet: After 10 minutes of blocking, 1:20 goat antihuman MUC3, MU-C5AC, MUC5B, and MUC6 polyclonal antibodies (Santa Cruz Inc., Santa Cruz, CA, USA) were added for 1 hour.

Techniques: Gene Expression, Control

Journal: Gut and Liver

Article Title: MUC Expression in Gallbladder Epithelial Tissues in Cholesterol-Associated Gallbladder Disease

doi: 10.5009/gnl15600

Figure Lengend Snippet: MUC gene expression in dog gallbladder epithelial cells (DG-BECs). Lipopolysaccharide-treated canine GBECs showed overexpression of both MUC3 and MUC5B mRNA compared to controls (p<0.05).

Article Snippet: After 10 minutes of blocking, 1:20 goat antihuman MUC3, MU-C5AC, MUC5B, and MUC6 polyclonal antibodies (Santa Cruz Inc., Santa Cruz, CA, USA) were added for 1 hour.

Techniques: Gene Expression, Over Expression